TLR9 and melanoma: In fact, it has been shown in stage I/III melanoma patients that the local administration of CpG-B (also called CpG 7909; PF-3512676), a TLR9 agonist, enhanced the activation state of pDCs and melanoma-specific CTLs responses and reduced Treg frequencies [68,69].